Oxaliplatin-induced hyperexcitation of rat sciatic nerve fibers: An intra-axonal study

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 373-379

  Kagiava, Alexia ^a,b   Kosmidis, Efstratios K ^c   Theophilidis, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Action potential; Colorectal cancer; Hyperexcitability; Intra axonal recordings; Oxaliplatin; Peripheral neuropathy; Sciatic nerve fiber

Indexed keywords

OXALIPLATIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEPTH RECORDING; CONTROLLED STUDY; EX VIVO STUDY; MALE; NERVE CELL STIMULATION; NERVE EXCITABILITY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROTOXICITY; NONHUMAN; RAT; REPOLARIZATION; SCIATIC NERVE;

ANIMALS; AXONS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NERVE FIBERS; ORGANOPLATINUM COMPOUNDS; POTASSIUM CHANNELS, VOLTAGE-GATED; RATS; RATS, WISTAR; SCIATIC NERVE; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 84876697553     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313020023     Document Type: Article

References (36)

1. De Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G.; Papamichael, D.; Le Bail, N.; Louvet, C.; Hendler, D.; De Braud, F.; Wilson, C.; Morvan, F.; Bonetti, A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol., 2000, 18(16), 2938-2947.
2. Andre, T.; Boni, C.; Mounedji-Boudiaf, L.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Zaninelli, M.; Clingan, P.; Bridgewater, J.; Tabah-Fisch, I.; de Gramont, A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med., 2004, 350(23), 2343-2351.
3. Raymond, E.; Chaney, S.G.; Taamma, A.; Cvitkovic, E. Oxaliplatin: A review of preclinical and clinical studies. Ann. Oncol., 1998, 9(10), 1053-1071.
4. Gamelin, E.; Gamelin, L.; Bossi, L.; Quasthoff, S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Semin Oncol., 2002, 29(5 Suppl 15), 21-33.
5. Grothey, A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol., 2003, 30 (4 Suppl 15), 5-13.
6. Wilson, R.H.; Lehky, T.; Thomas, R.R.; Quinn, M.G.; Floeter, M.K.; Grem, J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J. Clin. Oncol., 2002, 20(7), 1767-1774.
7. Lehky, T.J.; Leonard, G.D.; Wilson, R.H.; Grem, J.L.; Floeter, M.K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004, 29(3), 387-392.
8. Park, S.B.; Goldstein, D.; Lin, C.S.-Y.; Krishnan, A.V.; Friedlander, M.L.; Kiernan, M.C. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J. Clin. Oncol., 2009, 27(8), 1243-1249.
9. + channel kinetics on rat sensory neurons. Eur. J. Pharmacol., 2000, 406(1), 25-32.
10. Grolleau, F.; Gamelin, L.; Boisdron-Celle, M.; Lapied, B.; Pelhate, M.; Gamelin, E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol., 2001, 85(5), 2293-2297.
11. Webster, R.G.; Brain, K.L.; Wilson, R.H.; Jean, L.; Grem, J.L.; Vincent, A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage- gated sodium channels. Br. J. Pharmacol., 2005, 146(7), 1027-1039.
12. Sittl, R.; Lampert, A.; Huth, T.; Schuy, T.E.; Link, A.S.; Fleckenstein, J.; Alzheimer, C.; Grafe, P.; Carr, R.W. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current. Proc. Natl. Acad Sci. U. S. A., 2012, 109(17), 6704-6709.
13. Krishnan, A.V.; Goldstein, D.; Friedlander, M.; Kiernan, M.C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005, 32(1), 51-60.
14. Krishnan, A.V.; Goldstein, D.; Friedlander, M.; Kiernan, M.C. Oxaliplatin and axonal Na+ channel function in vivo. Clin. Cancer. Res., 2006, 12(15), 4481-4484.
15. Park, S.B.; Lin, C.S.Y.; Krishnan, A.V.; Goldstein, D.; Friedlander, M.L.; Kiernan, M.C. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PloS One, 2011, 6(4), e18469-18475.
16. Von Delius, S.; Eckel, F.; Wagenpfeil, S.; Mayr, M.; Stock, K.; Kullmann, F.; Obermeier, F.; Erdmann, J.; Schmelz, R.; Quasthoff, S.; Adelsberger, H.; Bredenkamp, R.; Schmid, R.M.; Lersch, C. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study. Invest. New Drugs, 2007, 25(2), 173-180.
17. Kiernan, M.C.; Lin, C.S.Y.; Andersen, K.V.; Murray, N.M.F.; Bostock, H. Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve, 2001, 24(7), 883-892.
18. Hart, I.K.; Maddison, P.; Newsom-Davis, J.; Vincent, A.; Mills, K.R. Phenotypic variants of autoimmune peripheral nerve hyper-excitability. Brain, 2002, 125(Pt 8), 1887-1895.
19. Kagiava, A.; Tsingotjidou, A.; Emmanouilides, C.; Theophilidis, G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibers of the adult rat. Neurotoxicology, 2008, 29(6), 1100-1106.
20. Kocsis, J.D.; Ruiz, J.A.; Waxman, S.G. Maturation of mammalian myelinated fibers: changes in action-potential characteristics following 4-aminopyridine application. J. Neurophysiol., 1983, 50(2), 449-463.
21. Benoit, E.; Brienza, S.; Dubois, J.M. Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen.Physiol.Biophys., 2006, 25(3), 263-276.
22. Sittl, R.; Carr, R.W.; Schwartz, J.R.; Grafe, P. The Kv7 pottasium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated sural nerve. J. Peripher. Nerv Syst., 2010, 15(1), 63-72.
23. Dimitrov, A.G.; Dimitrova, N.A. A possible link of oxaliplatin-induced neuropathy with potassium channel deficit. Muscle Nerve, 2012, 45(3), 403-411.
24. Kagiava, A.; Theophilidis, G. High concentrations of dichloroacetate have minor effects on the vitality of the mammalian nerve fibers: an ex-vivo electrophysiological study. Anticancer Drugs. 2011, 22(3), 273-276.
25. Eckel, F.; Schmelz, R.; Adelsberger, H.; Erdmann, J.; Quasthoff, S.; Lersch, C. Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch. Med. Wochenschr., 2002, 127(3), 78-82.
26. Schmalbruch, H. Fiber composition of the rat sciatic nerve. Anat. Rec., 1986. 215(1), 71-81.
27. + channels. J. Neurophysiol., 2002, 87(3), 1376-1385.
28. Eng, D.L.; Gordon, T.R.; Kocsis, J.D.; Waxman, S.G. Development of 4-AP and TEA sensitivities in mammalian myelinated nerve fibers. J. Neurophysiol., 1988, 60(6), 2168-2179.
29. Targ, E.; Kocsis, J.D. Action potential characteristics of demyelinated rat sciatic nerve following application of 4-aminopyridine. Brain Res., 1986, 363(1), 1-9.
30. Kagiava, A. The effects of stress conditions on the function of the sciatic nerve of vertebrates. PhD Thesis, Aristotle University of Thessaloniki: Thessaloniki, July 2011.
31. Gamelin, L.; Boisdron-Celle, M.; Delva, R.; Guérin-Meyer, V.; Ifrah, N.; Morel, A.; Gamelin, E. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res., 2004, 10(12 Pt 1), 4055-4061.
32. Wolf, J.; Richardson, P.G.; Schuster, M.; LeBlanc, A.; Walters, I.B.; Battleman, D.S. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin. Adv. Hematol. Oncol., 2008, 6(10), 755-760.
33. Graham, M.A.; Lockwood, G.F.; Greenslade, D.; Brienza, S.; Bayssas, M.; Gamelin, E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin. Cancer Res., 2000, 6(4), 1205-1218.
34. Schwarz, J.R.; Glassmeier, G.; Cooper, E.C.; Kao, T.C.; Nodera, H.; Tabuena, D.; Kaji, R.; Bostock, H. KCNQ channels mediate IKs, a slow K+ current regulating excitability in the rat node of Ranvier. J Physiol., 2006, 573(Pt 1), 17-34.
35. Izhikevich, E.M. Neural excitability, spiking and bursting. Internat. J. Bifur. Chaos Appl. Sci. Engrg., 2000, 10(6), 1171-1266.
36. Van Poucke, M.; Vanhaesebrouck, A.E.; Peelman, L.J.; Van Ham, L. Experimental validation of in silico predicted KCNA1, KCNA2, KCNA6 and KCNQ2 genes for association studies of peripheral nerve hyperexcitability syndrome in Jack Russell Terriers. Neuromuscul. Disord., 2012, 22(6), 558-565.